Sarepta Therapeutics, INC. 8-K Filing
Ticker: SRPT · Form: 8-K · Filed: Dec 19, 2025 · CIK: 873303
Sentiment: neutral
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-12-19 16:34:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT NASDAQ Glo
- $291.4 million — exchange with the Company approximately $291.4 million in aggregate principal amount of Existi
- $31.6 million — and (ii) an aggregate of approximately $31.6 million in cash. The New Convertible Notes we
- $602.0 million — of the same series as the approximately $602.0 million of 4.875% Convertible Senior Notes due
- $893.4 million — ior Notes due 2030 totals approximately $893.4 million. The foregoing description of the Fir
Filing Documents
- d32354d8k.htm (8-K) — 26KB
- d32354dex41.htm (EX-4.1) — 42KB
- 0001193125-25-326969.txt ( ) — 186KB
- srpt-20251218.xsd (EX-101.SCH) — 3KB
- srpt-20251218_lab.xml (EX-101.LAB) — 17KB
- srpt-20251218_pre.xml (EX-101.PRE) — 11KB
- d32354d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. By: /s/ Ian Estepan Ian Estepan President and Chief Operating Officer Date: December 19, 2025